Moderna cuts four programs in vaccines, solid tumors and heart failure as it increases, prioritizes pipeline
Moderna is beefing up its pipeline over the next five years with a plan launch up to 15 new products and advance up to 50 mRNA medicines into clinical trials — but not all programs made the cut as the company prioritizes.
Four programs were scrapped, according to Moderna’s R&D day presentation for investors. The list includes a first-generation Covid and flu combo vaccine and another vaccine for pediatric human metapneumovirus (hMPV) and parainfluenza type 3. Rounding out the list is an mRNA prospect for solid tumors that encoded for the cytokine IL-12, and another candidate that encoded for vascular endothelial growth factor A (VEGF-A) in patients undergoing coronary artery bypass grafting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.